Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 12, 2010, Pages 1611-1628

  Wolff, Daniel ^a   Gerbitz, Armin ^b   Ayuk, Francis ^c   Kiani, Alexander ^d   Hildebrandt, Gerhard C ^a   Vogelsang, Georgia B ^e   Elad, Sharon ^f   Lawitschka, Anita ^g   Socie, Gerard ^h   Pavletic, Steven Z ⁱ   Holler, Ernst ^a   Greinix, Hildegard ^j  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^g ST ANNA CHILDREN S HOSPITAL   (Austria)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease; Immunosuppressive therapy

Indexed keywords

AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; BUDENOFALK; BUDESONIDE; CALCINEURIN INHIBITOR; CLOBETASOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXA SINE; DEXAMETHASONE; EVEROLIMUS; FLUOCINONIDE; IMMUNOSUPPRESSIVE AGENT; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OPTORAL; PIMECROLIMUS; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; PSORALEN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; ATOPIC DERMATITIS; AVASCULAR NECROSIS; BLOOD TOXICITY; BRONCHIOLITIS OBLITERANS; BURN; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TREATMENT FAILURE; DRUG UPTAKE; DRUG WITHDRAWAL; ENTEROPATHY; EVENING DOSAGE; EYE DISEASE; FASCIITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INTERSTITIAL PNEUMONIA; LICHEN PLANUS; MORBIDITY; MORNING DOSAGE; MOUTH DISEASE; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ORGANIZING PNEUMONIA; PHOTOCHEMOTHERAPY; PHOTOTOXICITY; PROCTOCOLITIS; PROGNOSIS; PUVA; RECURRENT CANCER; RECURRENT INFECTION; SEDATION; SIDE EFFECT; SJOEGREN SYNDROME; SKIN ATROPHY; SKIN CANCER; SOMNOLENCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VULVA DISEASE;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDNISONE;

EID: 77957676790     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.015     Document Type: Article

References (111)

1. Akpek G., Zahurak M.L., Piantadosi S., et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001, 97:1219-1226.
2. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100:406-414.
3. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
4. Schultz K. Pathophysiology of chronic graft versus host disease. Chronic Graft versus Host Disease: Interdisciplinary Management 2009, 17-30. Cambridge University Press, New York. G. Vogelsang, S. Pavletic (Eds.).
5. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.
6. Shulman H.M., Kleiner D., Lee S.J., et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group report. Biol Blood Marrow Transplant 2006, 12:31-47.
7. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006, 12:375-396.
8. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
9. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.
10. Couriel D.R. Ancillary and supportive care in chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:291-307.
11. Arora M., Nagaraj S., Witte J., et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009, 43:149-153.
12. Cho B.S., Min C.K., Eom K.S., et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009, 23:78-84.
13. Jagasia M., Giglia J., Chinratanalab W., et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007, 13:1207-1215.
14. Vigorito A.C., Campregher P.V., Storer B.E., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009, 114:702-708.
15. Vogelsang G.B. How I treat chronic graft-versus-host disease. Blood 2001, 97:1196-1201.
16. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002, 100:48-51.
17. Sullivan K.M., Witherspoon R.P., Storb R., et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988, 72:555-561.
18. Sullivan K.M., Witherspoon R.P., Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988, 72:546-554.
19. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
20. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001, 7:265-273.
21. Koc S., Leisenring W., Flowers M.E., et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000, 96:3995-3996.
22. Choi C.J., Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 2001, 137:1202-1206.
23. Elad S., Or R., Resnick I., Shapira M.Y. Topical tacrolimus-a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 2003, 16:665-670.
24. Schmook T., Kraft J., Benninghoff B., et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005, 36:87-88.
25. Ziemer M., Gruhn B., Thiele J.J., Elsner P. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol 2004, 50:946-948.
26. Atkinson K., Weller P., Ryman W., Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986, 1:227-236.
27. Eppinger T., Ehninger G., Steinert M., Niethammer D., Dopfer R. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990, 50:807-811.
28. Ghoreschi K., Thomas P., Penovici M., et al. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. Eur J Dermatol 2008, 18:667-670.
29. Jampel R.M., Farmer E.R., Vogelsang G.B., Wingard J., Santos G.W., Morison W.L. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol 1991, 127:1673-1678.
30. Leiter U., Kaskel P., Krahn G., et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed 2002, 18:183-190.
31. Vogelsang G.B., Wolff D., Altomonte V., et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996, 17:1061-1067.
32. Calzavara P.P., Porta F., Izzi T., et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 2003, 88:1169-1175.
33. Grundmann-Kollmann M., Behrens S., Gruss C., Gottlober P., Peter R.U., Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000, 42(1 Pt 1):134-136.
34. Wetzig T., Sticherling M., Simon J.C., Hegenbart U., Niederwieser D., Al Ali H.K. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005, 35:515-519.
35. Ziemer M., Thiele J.J., Gruhn B., Elsner P. Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy: improvement of skin lesions, joint mobility, and quality of life. J Am Acad Dermatol 2004, 51:318-319.
36. Enk C.D., Elad S., Vexler A., Kapelushnik J., Gorodetsky R., Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant 1998, 22:1179-1183.
37. Andree H., Hilgendorf I., Leithaeuser M., et al. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. Bone Marrow Transplant 2008, 42:541-546.
38. Iyer R.V., Hahn T., Roy H.N., et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:587-592.
39. Villanueva F.N., Perez-Simon J.A., Silva F.F., et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:1331-1336.
40. Elad S., Or R., Garfunkel A.A., Shapira M.Y. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003, 95:308-311.
41. Sari I., Altuntas F., Kocyigit I., et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 2007, 82:349-356.
42. Schubert M.M., Correa M.E. Oral graft-versus-host disease. Dent Clin North Am 2008, 52. 79-ix.
43. Utsman R.A., Epstein J.B., Elad S. Budesonide for local therapy of complex oral mucosal immune-mediated inflammatory diseases: case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 106:e11-e17.
44. Wolff D., Anders V., Corio R., et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed 2004, 20:184-190.
45. Albert M.H., Becker B., Schuster F.R., et al. Oral graft vs. host disease in children-treatment with topical tacrolimus ointment. Pediatr Transplant 2007, 11:306-311.
46. Eckardt A., Starke O., Stadler M., Reuter C., Hertenstein B. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004, 40:811-814.
47. Epstein J.B., Reece D.E. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994, 13:81-86.
48. Epstein J.B., Truelove E.L. Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996, 82:532-536.
49. Fricain J.C., Sibaud V., Swetyenga N., Tabrizi R., Campana F., Taieb A. Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. Br J Dermatol 2007, 156:588-590.
50. Mawardi H, Stevenson K, Gokani B, Soiffer R, Treister N. Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant. 2020;45:1062-1067.
51. Sanchez A.R., Sheridan P.J., Rogers R.S. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 2004, 75:613-619.
52. Elad S., Garfunkel A.A., Enk C.D., Galili D., Or R. Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999, 88:444-450.
53. Menillo S.A., Goldberg S.L., McKiernan P., Pecora A.L. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation. Bone Marrow Transplant 2001, 28:807-808.
54. Redding S.W., Callander N.S., Haveman C.W., Leonard D.L. Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 86:183-187.
55. Marsh P., Pflugfelder S.C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999, 106:811-816.
56. Robinson M.R., Lee S.S., Rubin B.I., et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004, 33:1031-1035.
57. Kiang E., Tesavibul N., Yee R., Kellaway J., Przepiorka D. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant 1998, 22:147-151.
58. Lelli G.J., Musch D.C., Gupta A., Farjo Q.A., Nairus T.M., Mian S.I. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006, 25:635-638.
59. Sall K., Stevenson O.D., Mundorf T.K., Reis B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000, 107:631-639.
60. Wang Y., Ogawa Y., Dogru M., et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant 2008, 41:293-302.
61. Anderson M., Kutzner S., Kaufman R.H. Treatment of vulvovaginal lichen planus with vaginal hydrocortisone suppositories. Obstet Gynecol 2002, 100:359-362.
62. Cattaneo A., De Marco A., Sonni L., Bracco G.L., Carli P., Taddei G.L. [Clobetasol vs. testosterone in the treatment of lichen sclerosus of the vulvar region.]. Minerva Ginecol 1992, 44:567-571.
63. Jensen J.T., Bird M., Leclair C.M. Patient satisfaction after the treatment of vulvovaginal erosive lichen planus with topical clobetasol and tacrolimus: a survey study. Am J Obstet Gynecol 2004, 190:1759-1763.
64. Spiryda L.B., Laufer M.R., Soiffer R.J., Antin J.A. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant 2003, 9:760-765.
65. Kelekci H.K., Uncu H.G., Yilmaz B., Ozdemir O., Sut N., Kelekci S. Pimecrolimus 1% cream for pruritus in postmenopausal diabetic women with vulvar lichen simplex chronicus: a prospective non-controlled case series. J Dermatol Treat 2008, 19:274-278.
66. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
67. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
68. Lee S.J., Flowers M.E. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008, 2008:134-141.
69. Frey F.J., Ruegsegger M.K., Frey B.M. The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone. Br J Clin Pharmacol 1986, 21:183-189.
70. Curtis J.J., Galla J.H., Woodford S.Y., Lucas B.A., Luke R.G. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 1982, 22:42-47.
71. Ekka B.K., Bagga A., Srivastava R.N. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol 1997, 11:597-599.
72. Powell-Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978, 13:833-837.
73. Higman M.A., Vogelsang G.B. Chronic graft versus host disease. Br J Haematol 2004, 125:435-454.
74. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
75. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004, 104:3501-3506.
76. De Jesus J., Ghosh S., Hsu Y., et al. Tacrolimus in combination with steroids for the treatment of chronic GvHD. Biol Blood Marrow Transplant 2004, 10(Suppl):49.
77. Przepiorka D., Blamble D., Hilsenbeck S., Danielson M., Krance R., Chan K.W. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000, 26:601-605.
78. Flowers M. Traditional treatment of chronic graft-versus-host disease. Blood Marrow Transplant Rev 2002, 12:5-8.
79. Perez-Simon J.A., Encinas C., Silva F., et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the National Institutes of Health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant 2008, 14:1163-1171.
80. Flowers M.E., Apperley J.F., van Besien K., et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008, 112:2667-2674.
81. Greinix H.T., Volc-Platzer B., Rabitsch W., et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998, 92:3098-3104.
82. Apisarnthanarax N., Donato M., Korbling M., et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003, 31:459-465.
83. Couriel D.R., Hosing C., Saliba R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006, 107:3074-3080.
84. Foss F.M., DiVenuti G.M., Chin K., et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005, 35:1187-1193.
85. Messina C., Locatelli F., Lanino E., et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
86. Greinix H.T., Socie G., Bacigalupo A., et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006, 38:265-273.
87. Kanold J., Messina C., Halle P., et al. Update on extracorporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow Transplant 2005, 35(Suppl 1):S69-S71.
88. Kanold J., Merlin E., Halle P., et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007, 47:2276-2289.
89. Conrotto D., Carrozzo M., Ubertalli A.V., et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Transplantation 2006, 82:1113-1115.
90. Neuman D.L., Farrar J.E., Moresi J.M., Vogelsang G.B., Higman M.A. Toxic absorption of tacrolimus [corrected] in a patient with severe acute graft-versus-host disease. Bone Marrow Transplant 2005, 36:919-920.
91. Prot-Labarthe S., Therrien R., Champagne M.A., Duval M., Joubert C. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. Bone Marrow Transplant 2007, 40:295-296.
92. Dall'Amico R., Rossetti F., Zulian F., et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997, 97:848-854.
93. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007, 8:157-173.
94. Flowers M.E., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002, 100:415-419.
95. Horn T.D., Rest E.B., Mirenski Y., Corio R.L., Zahurak M.L., Vogelsang G.B. The significance of oral mucosal and salivary gland pathology after allogeneic bone marrow transplantation. Arch Dermatol 1995, 131:964-965.
96. Dilger K., Halter J., Bertz H., Lopez-Lazaro L., Gratwohl A., Finke J. Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:336-343.
97. Gorouhi F., Solhpour A., Beitollahi J.M., et al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 2007, 57:806-813.
98. Deeg H.J., Socie G., Schoch G., et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996, 87:386-392.
99. Chor A., Sotero Caio A.B., de Azevedo A.M. The irreplaceable image: amelioration of oral mucosal lesions of acute graft-versus-host disease by low-level laser therapy. Haematologica 2001, 86:1321.
100. Castilla C., Perez-Simon J.A., Sanchez-Guijo F.M., et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant 2006, 12:936-941.
101. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
102. Kim H., Csaky K.G., Gilger B.C., et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci 2005, 46:655-662.
103. Afessa B., Peters S.G. Chronic lung disease after hematopoietic stem cell transplantation. Clin Chest Med 2005, 26:571-586. vi.
104. Jung J.I., Jung W.S., Hahn S.T., Min C.K., Kim C.C., Park S.H. Bronchiolitis obliterans after allogenic bone marrow transplantation: HRCT findings. Korean J Radiol 2004, 5:107-113.
105. Schultz K.R., Green G.J., Wensley D., et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994, 84:3212-3220.
106. Yokoi T., Hirabayashi N., Ito M., et al. Broncho-bronchiolitis obliterans as a complication of bone marrow transplantation: a clinicopathological study of 8 autopsy cases. Nagoya BMT Group. Virchows Arch 1997, 431:275-282.
107. Yousem S.A. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995, 26:668-675.
108. Bergeron A., Belle A., Chevret S., et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:547-553.
109. Bashoura L., Gupta S., Jain A., et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:63-67.
110. Bergeron A., Chagnon K., Feuillet S., Chevret S., Tazi A. [Prospective evaluation of the efficacy of the combination of budesonide/formoterol in obstructive airway disease after allogeneic hematopoietic stem cell transplantation.]. Rev Mal Respir 2009, 26:794-800.
111. Cribier B., Frances C., Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998, 134:1521-1530.